Log In
Print
BCIQ
Print
Print this Print this
 

Oblean, cetilistat (Cametor) (ATL-962)

  Manage Alerts
Collapse Summary General Information
Company Norgine B.V.
DescriptionOral lipase inhibitor
Molecular Target Lipase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationObesity
Indication DetailsTreat obesity; Treat obesity in diabetic patients; Treat obesity in patients with complications; Treat obesity in patients with Type II diabetes and dyslipidemia
Regulatory Designation

Japan - Standard Review (Treat obesity in patients with Type II diabetes and dyslipidemia)

Partner

Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today